Apolipoprotein C-III

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Retrieved on: 
Thursday, May 2, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Small RNA, AMGN, RNA interference, Risk, Partnering, Arrowhead, APOC3, Moyamoya disease, RNA, Apolipoprotein C-III, Trial, Patient, Myocardial infarction, Cardiovascular disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).
  • This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN).
  • Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.
  • “Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Completeness, ANGPTL3, NASDAQ, RNA, Company, Safety, Patient, Trial of the century, APOC3, Webcast, Apolipoprotein C-III, RNA interference, PNH, Adult, Conference, PALISADE, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022.
  • The company is hosting a conference call today, May 10, 2022, at 4:30 p.m.
  • For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3791265.
  • An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days.

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

Retrieved on: 
Wednesday, February 2, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Webcast, APOC3, Safety, American Association, Patient, NASDAQ, Janssen Pharmaceuticals, Trial of the century, Apolipoprotein C-III, NASH, Johnson & Johnson, Annual general meeting, AASLD, PALISADE, CTAS, GSK, Company, RNA interference, Association, Fatty liver disease, CTA, Foot, Conference, RNA, Liver disease, GlaxoSmithKline, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2021.
  • The company is hosting a conference call today, February 2, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 9844328.

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

Retrieved on: 
Thursday, June 3, 2021
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Clinical research, Health sciences, Medical research, Health, Design of experiments, Apolipoprotein C-III, Apolipoproteins, Drug discovery, Pharmaceutical industry, Arrowhead Pharmaceuticals, Clinical trial, Placebo

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG).
  • Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021.
  • We believe there remains a significant need for new therapies that can substantially lower and sustain triglyceride levels in patients with severe hypertriglyceridemia.
  • AROAPOC3-2001 is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of ARO-APOC3 in adults with SHTG.

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Retrieved on: 
Monday, March 1, 2021
Health, FDA, Genetics, Clinical trials, Research, Science, Pharmaceutical, Health sciences, Health, Medical research, Clinical research, Design of experiments, Drug discovery, Pharmaceutical industry, Lipid metabolism disorders, Clinical trial, Apolipoprotein C-III, Dose-ranging study, Lipoprotein lipase deficiency

Based on these highly promising results, we intend to conduct Phase 2b and Phase 3 clinical studies across a wide spectrum of patient populations, pending review by regulators.

Key Points: 
  • Based on these highly promising results, we intend to conduct Phase 2b and Phase 3 clinical studies across a wide spectrum of patient populations, pending review by regulators.
  • Following the FDAs review of the IND, the company intends to initiate a Phase 2b dose-finding clinical study (ARO-APOC3-2001) in patients with severe hypertriglyceridemia (sHTG).
  • Additional clinical studies planned in 2021 include a Phase 2b dose-finding clinical study in patients with mixed dyslipidemia and a Phase 3 clinical study in patients with familial chylomicronemia syndrome (FCS).
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.